This post was written by Paul Sheives. FDA has issued a guidance document entitled “Bioequivalence Recommendations for Specific Products,” which announces that FDA will make available recommendations on study design for particular products on the agency’s website. In the past, applicants of abbreviated new drug applications had to request this information; FDA hopes that making this information more readily available will help streamline the guidance process.